Significant proportion of cancer drugs lack proof of added benefit

The BMJ

High Factuality

Significant proportion of cancer drugs lack proof of added benefit

Particularly those approved through “fast track” pathways Many cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved through expedited (“fast track”) pathways, finds a study published by The BMJ today. And despite pharmaceutical industry claims that high drug prices are needed to offset research and